Alyce S Adams1, Jeanne M Madden2, Fang Zhang3, Christine Y Lu3, Dennis Ross-Degnan3, Angelina Lee4, Stephen B Soumerai3, Dan Gilden4, Neetu Chawla5, Jennifer J Griggs6. 1. Kaiser Permanente Division of Research, Oakland, CA, USA. Electronic address: Alyce.S.Adams@kp.org. 2. School of Pharmacy, Northeastern University, Boston, MA, USA; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. 3. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. 4. Jen Associates, Inc., Cambridge, MA, USA. 5. Kaiser Permanente Division of Research, Oakland, CA, USA. 6. Departments of Internal Medicine, Hematology/Oncology, and Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
Abstract
OBJECTIVES: To evaluate the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer. METHODS: We leveraged a representative 5% national sample of all fee-for-service dual enrollees in the United States (2004-2007) to evaluate the impact of the removal of caps on the number of reimbursable prescriptions per month (drug caps) under Part D on 1) prevalence and 2) average days' supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall and by race (white and black). RESULTS: The removal of drug caps was associated with increased use of lipid-lowering medications (days' supply 3.63; 95% confidence interval [CI] 1.57-5.70). Among blacks in capped states, we observed increased use of lipid-lowering therapy (any use 0.08 percentage points; 95% CI 0.05-0.10; and days' supply 4.01; 95% CI 2.92-5.09) and antidepressants (days' supply 2.20; 95% CI 0.61-3.78) and increasing trends in antihypertensive use (any use 0.01 percentage points; 95% CI 0.004-0.01; and days' supply 1.83; 95% CI 1.25-2.41). The white-black gap in the use of lipid-lowering medications was immediately reduced (-0.09 percentage points; 95% CI -0.15 to -0.04). We also observed a reversal in trends toward widening white-black differences in antihypertensive use (level -0.08 percentage points; 95% CI -0.12 to -0.05; and trend -0.01 percentage points; 95% CI -0.02 to -0.01) and antidepressant use (-0.004 percentage points; 95% CI -0.01 to -0.0004). CONCLUSIONS: Our findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
OBJECTIVES: To evaluate the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer. METHODS: We leveraged a representative 5% national sample of all fee-for-service dual enrollees in the United States (2004-2007) to evaluate the impact of the removal of caps on the number of reimbursable prescriptions per month (drug caps) under Part D on 1) prevalence and 2) average days' supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall and by race (white and black). RESULTS: The removal of drug caps was associated with increased use of lipid-lowering medications (days' supply 3.63; 95% confidence interval [CI] 1.57-5.70). Among blacks in capped states, we observed increased use of lipid-lowering therapy (any use 0.08 percentage points; 95% CI 0.05-0.10; and days' supply 4.01; 95% CI 2.92-5.09) and antidepressants (days' supply 2.20; 95% CI 0.61-3.78) and increasing trends in antihypertensive use (any use 0.01 percentage points; 95% CI 0.004-0.01; and days' supply 1.83; 95% CI 1.25-2.41). The white-black gap in the use of lipid-lowering medications was immediately reduced (-0.09 percentage points; 95% CI -0.15 to -0.04). We also observed a reversal in trends toward widening white-black differences in antihypertensive use (level -0.08 percentage points; 95% CI -0.12 to -0.05; and trend -0.01 percentage points; 95% CI -0.02 to -0.01) and antidepressant use (-0.004 percentage points; 95% CI -0.01 to -0.0004). CONCLUSIONS: Our findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
Authors: Joan L Warren; Eboneé N Butler; Jennifer Stevens; Christopher S Lathan; Anne-Michelle Noone; Kevin C Ward; Linda C Harlan Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Nancy K Janz; Mahasin S Mujahid; Sarah T Hawley; Jennifer J Griggs; Amy Alderman; Ann S Hamilton; John Graff; Steven J Katz Journal: J Cancer Surviv Date: 2009-09-16 Impact factor: 4.442
Authors: Joeëlle Y Friedman; Lesley H Curtis; Bradley G Hammill; Jatinder K Dhillon; Charles H Weaver; Sugata Biswas; Amy P Abernethy; Kevin A Schulman Journal: Cancer Date: 2007-11-15 Impact factor: 6.860
Authors: Alisa M Shea; Lesley H Curtis; Bradley G Hammill; Lisa D DiMartino; Amy P Abernethy; Kevin A Schulman Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Carrie N Klabunde; Paul K J Han; Craig C Earle; Tenbroeck Smith; John Z Ayanian; Richard Lee; Anita Ambs; Julia H Rowland; Arnold L Potosky Journal: Fam Med Date: 2013 Jul-Aug Impact factor: 1.756